Insights
Search Results
Client Highlights
6.02.26
Firm Advises Noctrix on Acquisition by Resmed
On June 1, 2026, Resmed, a medical device company that develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders, announced it has closed on its acquisition of Noctrix Health, a medical device company that developed and manufactures a novel therapy to treat drug-refractory Restless Legs Syndrome (RLS) for $340 million. Wilson Sonsini Goodrich & Rosati advised Noctrix on the transaction.
Client Highlights
2.21.25
Wilson Sonsini Advises Anaerobe Systems on Acquisition by Biolog
On February 12, 2025, Biolog, a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification services, announced the acquisition of Anaerobe Systems. The acquisition will be funded through a financing led by J.P. Morgan Life Sciences Private Capital with participation from existing investors BroadOak Capital Partners and Research Corporation Technologies. Wilson Sonsini Goodrich & Rosati advised Anaerobe Systems on the transaction.
Client Highlights
1.15.25
Wilson Sonsini Advises Aerin on $32.5 Million Equity Fundraise, New Debt Facility
On January 13, 2025, Aerin Medical, a medical device company focused on expanding access to meaningful relief for millions of patients suffering from chronic ENT conditions, announced the successful completion of two significant financial transactions. These transactions position Aerin Medical to drive additional commercial growth, advance market-leading innovation, and further expand its robust clinical evidence portfolio. The $32.5 million equity financing was led by all of Aerin's major investors: KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation by Ares Management Credit funds, which also provided Aerin a debt facility to refinance its existing debt and access additional capital.
Client Highlights
2.08.22
Wilson Sonsini Advises Enable Injections on $215 Million Series C
On January 27, 2022, Enable Injections, Inc., a company developing and manufacturing the enFuse platform of investigational wearable drug delivery systems, announced $215 million in Series C financing. Magnetar Capital led the financing along with new institutional investments from GCM Grosvenor, Squarepoint Capital, Woody Creek Capital Partners, and other investors. Enable received significant continued support from existing investors including Cincinnati Children's Hospital Medical Center, CincyTech, Cintrifuse, and Ohio Innovation Fund. Wilson Sonsini Goodrich & Rosati advised Enable Injections on the transaction.